Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Operating Expenses (2016 - 2025)

Cytokinetics (CYTK) has disclosed Operating Expenses for 16 consecutive years, with $301.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Expenses changed N/A to $301.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $805.7 million, a N/A change, with the full-year FY2025 number at $700.3 million, up 26.24% from a year prior.
  • Operating Expenses was $301.5 million for Q4 2025 at Cytokinetics, up from $168.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $301.5 million in Q4 2025 to a low of $47.2 million in Q1 2021.
  • A 5-year average of $125.5 million and a median of $127.1 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 104.47% in 2021, then fell 1.56% in 2024.
  • Cytokinetics' Operating Expenses stood at $77.3 million in 2021, then soared by 66.86% to $129.0 million in 2022, then increased by 0.08% to $129.1 million in 2023, then grew by 9.43% to $141.3 million in 2024, then skyrocketed by 113.46% to $301.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Operating Expenses are $301.5 million (Q4 2025), $168.7 million (Q3 2025), and $178.3 million (Q2 2025).